000			03236nam a22004815i 4500
001			u373222
003			SIRSI
005			20160812084136.0
007			cr nn 008mamaa
008			100301s2010 gw | s |||| 0|eng d
020			_a9783540782810 _9978-3-540-78281-0
040			_cMX-MeUAM
050		4	_aRC254-282
082	0	4	_a616.994 _223
100	1		_aLiersch, Rüdiger. _eeditor.
245	1	0	_aAngiogenesis Inhibition _h[recurso electrónico] / _cedited by Rüdiger Liersch, Wolfgang E. Berdel, Torsten Kessler.
264		1	_aBerlin, Heidelberg : _bSpringer Berlin Heidelberg, _c2010.
300			_aXIV, 231 p. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	1		_aRecent Results in Cancer Research, _x0080-0015 ; _v180
505	0		_aAngiopoietins -- HIF-1? and Cancer Therapy -- Chemokines -- Angiogenesis Inhibition in Cancer Therapy -- Vascular Integrins: Therapeutic and Imaging Targets of Tumor Angiogenesis -- PDGF and Vessel Maturation -- Lymphangiogenesis in Cancer: Current Perspectives -- Compounds in Clinical Phase III and Beyond -- Metronomic Chemotherapy: Principles and Lessons Learned from Applications in the Treatment of Metastatic Prostate Cancer -- Targeting Inflammatory Cells to Improve Anti-VEGF Therapies in Oncology -- Antibody-Based Vascular Tumor Targeting -- Caveolae and Cancer.
520			_aAngiogenesis is attracting increased scientific and clinical interest. The identification of novel mediators and targeting molecules has led to significant progress in our understanding of tumor angiogenesis and tumor vessel targeting. Important advances in cancer treatment have already emerged, and in the future, blood vessel targeting will play a significant role within individualized therapeutic strategies. This volume provides a general overview of the latest developments in angiogenesis inhibition in cancer. All aspects from the bench to the bedside are considered, with detailed attention both to basic research and to its translation into clinical practice. Individual chapters are devoted to the roles of angiopoietins, HIF-1a, chemokines, PDGF and VEGF, and vascular integrins. The latest results of clinical trials on therapeutic compounds are presented, and various advanced targeting strategies are discussed. This book will be invaluable to all who wish to learn of the most recent advances in research and treatment in this exciting field.
650		0	_aMedicine.
650		0	_aOncology.
650		0	_aHematology.
650	1	4	_aMedicine & Public Health.
650	2	4	_aOncology.
650	2	4	_aHematology.
650	2	4	_aCancer Research.
700	1		_aBerdel, Wolfgang E. _eeditor.
700	1		_aKessler, Torsten. _eeditor.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9783540782803
830		0	_aRecent Results in Cancer Research, _x0080-0015 ; _v180
856	4	0	_zLibro electrónico _uhttp://148.231.10.114:2048/login?url=http://link.springer.com/book/10.1007/978-3-540-78281-0
596			_a19
942			_cLIBRO_ELEC
999			_c201102 _d201102